Bootstrap simulations to estimate relationships between Type I error, power, effect size, and appropriate sample numbers for bioassessments of aquatic ecosystems.

J Environ Sci Health A Tox Hazard Subst Environ Eng

Wye Research and Education Center, Agricultural Experiment Station, College of Agriculture and Natural Resources, University of Maryland, Queenstown, Maryland, USA.

Published: January 2021

The Extended Bootstrap (EB) assessment approach was developed for the examination of relationships of Type I error, power, sample size (), and effect size (ES) for statistical tests of ecological data. The EB approach was applied to univariate and multivariate statistical analyses of a large data set collected from an ongoing, multiple stressor bioassessment study of watersheds in the Central Valley, San Francisco, and Central Coast areas of California. Benthic metrics were created that either increased or decreased monotonically with stress (toxicants or metrics indicative of habitat quality). Type I errors were stable for all statistical tests that were evaluated. The relationships between and ES displayed patterns of "diminishing returns" for all statistical tests: i.e. an increasingly larger was required to detect decreasingly smaller ES. Nonetheless, the 's collected across the watersheds and within a selected watershed were sufficient to detect even small correlations between representative benthic metrics and potential stressors with high power. The power and robustness of a novel method using EB and previously described statistical techniques designed to address multicollinearity were shown to approach those of simpler univariate regressions. Potential applications of the EB approach for experimental design, data assessment and interpretation, and hypothesis testing are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10934529.2020.1809924DOI Listing

Publication Analysis

Top Keywords

statistical tests
12
relationships type
8
type error
8
error power
8
benthic metrics
8
statistical
5
bootstrap simulations
4
simulations estimate
4
estimate relationships
4
power
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Loma Linda University Health, Loma Linda, CA, USA.

Background: Only about 50% of the variance in cognitive decline occurring during Alzheimer's pathogenesis is attributable to standard AD biomarkers (cerebrocortical Aβ, pathological tau, and atrophy) (Tosun et al., Alzheimer's Dement. 18: 1370, 2022).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: The Mini-Mental State Examination (MMSE) is a common screening tool in Alzheimer's disease (AD) clinical trials. MMSE score inflation at inclusionary visits poses challenges by potentially amplifying placebo responses and complicating the detection of treatment effects. Despite these concerns, prior research (e.

View Article and Find Full Text PDF

Numerous drugs (including disease-modifying therapies, cognitive enhancers and neuropsychiatric treatments) are being developed for Alzheimer's and related dementias (ADRD). Emerging neuroimaging modalities, and genetic and other biomarkers potentially enhance diagnostic and prognostic accuracy. These advances need to be assessed in real-world studies (RWS).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.

Background: Randomized placebo-controlled trials (RCTs) are the gold standard to evaluate efficacy of new drug treatments for Alzheimer's disease. For example, the United States FDA approved the brain amyloid-targeting drug lecanemab following CLARITY AD, Biogen and Eisai's Phase 3 RCT. However, recruiting enough participants for a high-powered and demographically representative trial is difficult and expensive.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!